American Society of Hematology

Press Releases

Subscribe to RSS
  • Stephanie Lee, MD, MPH, Begins Term as 2020 ASH President Jan 10, 2020

    Stephanie Lee, MD, MPH, a highly regarded expert in graft-versus-host disease as well as blood and bone marrow diseases, will serve as president of the American Society of Hematology for a year-long term through December 2020.

  • Metabolic syndrome associated with increased risk of blood clot recurrence Jan 09, 2020

    People with metabolic syndrome – a set of conditions including obesity, impaired glucose metabolism, elevated levels of fats and cholesterol in the blood, and high blood pressure – are more likely to experience recurrent blood clots, according to a new study published today in Blood Advances.

  • New Study Finds Blood Clots More Likely in Children Who Receive Peripherally Inserted Central Catheters Jan 07, 2020

    A new study provides convincing evidence that the use of peripherally inserted central catheters (PICCs) to administer medicine and draw blood in children is associated with a significantly increased risk of blood clots (known as venous thromboembolism or VTE) compared with central venous catheters (CVCs) placed directly into the neck or chest.

  • Statement from ASH President Stephanie Lee, MD, on Proposed Administration Policy to Change Open Access Peer Reviewed Journals Dec 19, 2019

    Yesterday, the American Society of Hematology (ASH) sent a letter to President Trump outlining concerns with a proposed policy that would jeopardize the intellectual property of American organizations engaged in the creation of high-quality peer-reviewed journals and research articles. The Administration is considering an Executive Order that would mandate that scientific articles reporting on federally funded research be made immediately available to everyone upon publication, eliminating or reducing the current 12-month embargo period that has been in place since 2008.


  • American Society of Hematology Announces 2020 Scholar Award Recipients Dec 19, 2019

    ASH today announced the 39 recipients of its 2020 Scholar Awards. One of ASH’s most prestigious research award programs, the ASH Scholar Awards financially support fellows to junior faculty dedicated to careers in hematology research as they transition from training programs to careers as independent investigators.

  • ASH President Commends Congress for Reaching Federal Spending Deal Dec 18, 2019

    On Monday, bipartisan leaders in the House and Senate reached an agreement on a $1.3 trillion federal spending deal for fiscal year 2020. The legislation package – which Congress is expected to pass and then submit to President Trump for signature this week – includes increased funding for vital public health agencies.

  • Encouraging Results Seen with Novel Approach to Gene Therapy for Sickle Cell Disease Dec 10, 2019

    Three adult patients with sickle cell disease (SCD) are doing well after receiving an infusion of their own stem cells that had been genetically engineered to induce them to stop producing harmful “sickle” hemoglobin and start producing a healthy form of hemoglobin, according to a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.

  • New Drug Markedly Improves Overall Survival in Patients with AML in Remission Dec 10, 2019

    Using an investigational oral form of azacitidine therapy, CC-486, significantly improved overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard induction chemotherapy with or without consolidation therapy, according to a phase III study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.

  • Phase III Trial Finds Sutimlimab Effective Against Cold Agglutinin Disease Dec 10, 2019

    Patients with cold agglutinin disease (CAD) had improved hemoglobin levels, required fewer blood transfusions, and felt significantly less fatigued after receiving the experimental drug sutimlimab for 26 weeks in a phase III clinical trial.

  • Study Reveals Genetic Underpinnings of AML and Myelodysplastic Syndrome Dec 10, 2019

    Researchers have completed the first comprehensive analysis combining full genomic sequencing and gene expression profiles of more than 1,300 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

1 of 46
back to top